

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room W-066-0609 Silver Spring, MD 20993-0002

Mr. Foo Khon Pu GX Corporation Sdn Bhd Lot 6487A, Batu 5 ¾, Sementa, Jalan Kapar, 42100 Klang Selangor Darul Ehsan MALAYSIA

NOV - 2 2009

Re: K091643

Trade/Device Name: Powder Free Latex Examination Gloves, Blue Tested for Use

With Chemotherapy Drugs

Regulation Number: 21 CFR 880.6250

Regulation Name: Patient Examination Glove

Regulatory Class: I Product Code: LZC

Dated: September 3, 2009 Received: October 8, 2009

Dear Mr. Pu:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRH
Offices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's)
Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Susan Runner, D.D.S., M.A.

Acting Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

Indications for Use

510(k) Number (if known):

Device Name:	Powder Free Latex Examina Tested For Use With Chemo	
Indication For U	se:	
	sposable device intended for n to prevent contamination betw	nedical purposes that is worn on the een patient and examiner.
-		OTIC), Cyclophosphamide (Cytoxan), platin, Etoposide, Paclitaxel (taxol)
Warning: Not Re	commended For Use With Car	mustine and Thio-Tepa
Prescription Use (Part 21 CFR 801 Subpar	AND/OR	Over-The-Counter Use X (21 CFR 801 Subpart C)
(PLEASE DO NOT NEEDED)	WRITE BELOW THIS LINE	- CONTINUE ON ANOTHER PAGE IF
Co	oncurrence of CDRH, Office O	f Device Evaluation (ODE)
	(Division Sign-Off) Division of Anesthesiology, Gen Infection Control, Dental Device	eral Hospital Page 1 of
510(k) Number: <u>K091643</u>		